STOP-GAP
11 Nov 2020
Trial Summary
The purpose of this study is to compare the effects on patients with metastatic melanoma of taking a government approved and paid-for PD-1 inhibitor intermittently, with taking the same type of agent continuously.
Acronym:
STOP-GAP
ACTRN/NCT /ethics:
NCT02821013
Scientific title:
A Randomized Phase-III Study of Duration of Anti-PD-1 Therapy in Metastatic Melanoma
Sponsor / Cooperative group:
Canadian Cancer Trials Groups
Trial & Patient Characteristics
| Cancer Type | Melanoma & other skin |
|---|---|
| Trial Type | Treatment |
| Phase | Phase III |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | Melanoma |
| Cancer Stage | Metastatic or Widespread |
| Anticipated Start Date | 2016-07-04 |
| Anticipated End Date | 2029-12-31 |
Participating Hospitals
| Hospital | The Queen Elizabeth Hospital |
|---|---|
| Clinical Trial Coordinator | Pamela Cooper |
| pamela.cooper@sa.gov.au | |
| Phone | 08 8222 6140 |
| Principal Investigator | Dr Rachel Roberts-Thomson |
| Recruitment Status | Recruiting |